JBIO - Jade Biosciences, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$46.71
DETAILS
HIGH:
$55.00
LOW:
$40.00
MEDIAN:
$47.00
CONSENSUS:
$46.71
UPSIDE:
119.40%
About Jade Biosciences, Inc. (https://jadebiosciences.com)
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Tom Frohlich | President, CEO & Director | 1976 | $1,019,883 USD |
| Andrew James King | President of Research & Development | 1980 | $765,901 USD |
| Bradford D. Dahms | CFO & Treasurer | 1989 | $350,051 USD |
| Amy Sullivan | Senior Vice President of Development Operations | – | – |
| Edward R. Conner | Chief Medical Officer | 1973 | – |
| Elizabeth Balta | Chief Legal Officer & Corporate Secretary | 1971 | – |
| Jonathan Quick | Senior Vice President of Finance | – | – |
| Lori Stewart | Senior Vice President of People | – | – |
| Sandy Lewis | Senior Vice President, Biometrics & Clinical Strategy | – | – |
| Valerie Fauvelle | Senior Vice President of Regulatory & Quality | – | – |